2:00 PM - 6:00 PM

9:00 AM - 6:30 PM

9:00 AM - 1:50 PM

The COVID-19 pandemic has placed infection research into the spotlight, highlighting once again the complexity and devastating impact that infectious diseases can have. In the new world where communicable diseases are taking center stage, having solid infectious disease pharmacology knowledge is essential for patient care.

This course is a remarkable platform for learning, networking, and advancing our understanding of clinical pharmacology in the context of HIV, hepatitis, COVID-19, and other bacterial and fungal infections.

Bringing together experts from different fields, the course features interactive sessions and lively debate, all offering ample opportunities for engaging discussions and knowledge exchange.

Not only designed for clinicians involved in HIV management who wish to deepen their knowledge about PK/PD aspects of HIV research and medicine, the 3-day course is also a focus on novel issues covering proper use of MoAb and patient’s prophilaxis, prescribing and monitoring procedures for a variety of drug regimens used to treat infectious diseases.  Each topic focuses on preclinical, translational and clinical aspects and will be a valuable experience for all involved in infectious diseases, as researchers or prescribers of anti-infective agents.

Upon completion of this course, participants will be better able to:

• Recognize the role of PK/PD parameters for the management of infections.
• Focus on recent developments regarding PK variability of antinfective drugs and its association with specific tissue drug penetration and clearance.
• Describe the challenges of HIV and viral hepatitis treatment as it relates to cure and selection of drug resistance.
• Discuss treatment optionsfor COVID-19 in high-risk groups, focusing on drug strategies and patient immune system response.
• Explore the pattern of use of monoclonal antibodies antiviral therapies approved for early COVID-19 treatment in non-hospitalized and hospitalized patients
• Discuss treatment optionsfor bacterial and fungal infections, focusing on drug strategies and patient immune system response.
• Develop strategies to modify treatment regimens based on individual patient response.
• Devise a plan to manage drug interactions and adverse effects anti-infective treatments and optimize treatment responses.
• Present real and typical clinical scenarios, discuss findings and management in the light of current PK/PD data and clinical practices guidelines.
• 
  

HealthData Consulting S.r.l. 

via Morghen 27, 10143 Turin, Tel. +39 011 0267950 - Fax +39 011 0267954 - Mail segreteria@hdcons.it, P.IVA 01429280058, REA 1125824